← Tilbage til Nyheder & Begivenheder kategori

Emerson køber Life Sciences Analytics Software Firm til at hjælpe Accelerate Manufacturing Production

emerson køber life science analytics software firma

Bio-G’s modelling, simulation and scheduling software helps dynamically optimise operations and streamline technology transfer

Emerson has acquired Bioproduction Group (Bio-G), a leader in simulation, modelling, and scheduling software for biomanufacturing. Bio-G’s scheduling and modelling systems combined with Emerson’s extensive life sciences technology and expertise portfolio will help companies bring therapies for cancer, diabetes and other illnesses to patients sooner.

Biovidenskabsvirksomheder ser løbende på at fremskynde produktionen af ​​patientterapier, og Bio-G Scheduling-softwaren hjælper dem med nøjagtigt at forudsige fremtidig tilgængelighed af planteressourcer for at optimere fremstillingsproduktionen.

Planlægningssoftwaren giver en øjeblikkelig visning, der er tilgængelig på tværs af en organisation, i den nuværende og fremtidige tilstand af anlægget, hvilket giver beslutningsstøtte for at bidrage til at øge opetidets driftstid og reducere tidsplanrelaterede produkttab.

By connecting analytics and modelling tools with data from automation and operations systems—including Emerson’s DeltaV™ distributed control system and Syncade™ manufacturing execution system—the scheduling software provides a unified view of operations, maintenance, quality and corporate systems.

Bio-G’s software will become a part of Emerson’s Plantweb™ digital ecosystem, a comprehensive IIoT portfolio that expands digital intelligence to the entire manufacturing enterprise.

“We continue to work closely with industry leaders to develop the manufacturing technologies and approaches needed for next-generation biomanufacturing. With this acquisition, we can deliver even more ways to accelerate life sciences manufacturing,” sagde Tom Snead, biovidenskabspræsident i Emerson.

Organisations invest hundreds of millions of dollars building manufacturing facilities to bring medicines and therapies to patients. The success of those efforts and their operations often depends on the facility’s actual production meeting the facility’s designed production.

Bio-G’s Real-Time Modelling System™ provides debottlenecking, capacity engineering and technology transfer analytics to deliver a comprehensive evaluation of a facility’s design and provide confidence prior to project execution and capital expenditure.

Modelleringsrammen identificerer og kvantificerer nøjagtigt flaskehalse samt bestemmer effektiviteten af ​​foreslåede løsninger på tværs af alle områder af et produktionsanlæg.

This modelling system helps accelerate the process of bringing therapies from clinical trials to full-scale manufacturing to patients by validating a facility’s potential for manufacturing success.

“We’re excited to join Emerson,” said David Zhang, Bio-G’s CEO and co-founder, who will be joining Emerson. “We’re united by a common mission to help innovate and find new ways for biomanufacturing organisations to optimise operations through technology.”

Kontakt information

[Email protected]
www.Emerson.com
www.bio-g.com

Emerson Automation Solutions

Signatur: Sølv medlemskab

Relaterede nyheder

Giv en kommentar

Din e-mail adresse vil ikke blive offentliggjort. Krævede felter er markeret *

Dette websted bruger Akismet til at reducere spam. Lær, hvordan dine kommentardata behandles.